Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on June 14, 2018. The report addresses a notice received from the NYSE American regarding the company's failure to meet continued listing standards based on its financial position as of March 31, 2018.
Key Financial Metrics
- Stockholders' Equity: $0.8 million as of March 31, 2018.
- Profitability: The company reported net losses in each of its five most recent fiscal years ended December 31, 2017.
- Revenue, Cash Flow, and Debt: The filing text does not provide specific values for revenue, cash flow, or debt levels.
Material Changes and Listing Status
The company is not in compliance with NYSE American Section 1003(a)(i), (ii), or (iii) due to insufficient stockholders' equity relative to its history of net losses. Specifically, the company failed to meet the minimum equity thresholds of $2.0 million, $4.0 million, or $6.0 million required for companies with losses in two, three, or five of their most recent fiscal years, respectively.
Outlook, Risks, and Compliance Plan
Cormedix is now subject to Section 1009 of the NYSE American Company Guide. The company must submit a plan of compliance to the exchange by July 16, 2018, detailing how it intends to regain compliance with the equity standards by December 16, 2019. If the plan is accepted, the company may continue listing during this period subject to periodic review. Failure to comply with the standards or make progress consistent with the plan will result in the initiation of delisting proceedings.
Key Facts for Investor Verification
- Verify the specific details of the compliance plan to be submitted by July 16, 2018.
- Monitor the company's stockholders' equity and profitability trends to assess the feasibility of meeting the December 16, 2019 deadline.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the situation.
- Confirm whether the company has initiated any capital raising activities to address the equity shortfall.